Eli Lilly & Co.
LLY (NYSE)
Eli Lilly & Co. is a standout pick for 2026, particularly with its promising growth in diabetes and obesity drugs such as Zepbound, which will soon benefit from Medicare deals starting in April 2026. With a robust 5-year return of 378.65% and a current dividend yield of 0.60%, this stock presents an attractive option for long-term investors. Analysts are optimistic, with a median 12-month price target of $1,280, signaling potential for continued growth despite recent mixed ratings from major firms.
Pros:
- Growth in diabetes and obesity drugs
- Strong market position
Cons:
- Recent stock pullback
- High valuation concerns
Eli Lilly & Co. (LLY) may be a suitable investment for long-term investors seeking exposure to the healthcare sector, particularly those interested in companies with innovative product pipelines and significant growth potential. With solid historical performance and upcoming opportunities related to Medicare deals, it may appeal to those who can tolerate moderate volatility in pursuit of substantial returns.